Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKT1 | P31749 | 13/20 | 0.40 |
| ▸ | PDPK1 | O15530 | 3/20 | 0.40 |
| ▸ | PHLPP1 | O60346 | 3/20 | 0.40 |
| ▸ | ILK | Q13418 | 3/20 | 0.40 |
| ▸ | ALOX5 | P09917 | 3/20 | 0.35 |
| ▸ | NR1I2 | O75469 | 2/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | BCHE | P06276 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL966916 | 0.88 | AKT1 (0.44) | AKT1PDPK1PHLPP1ILKALOX5 | |
| SCHEMBL12919863 | 0.88 | AKT1 (0.43) | AKT1PDPK1PHLPP1ILKALOX5 | |
| SCHEMBL968746 | 0.86 | AKT1 (0.42) | AKT1PDPK1PHLPP1ILKALOX5 | |
| SCHEMBL12919859 | 0.83 | AKT1 (0.48) | AKT1PDPK1PHLPP1ILKALOX5 | |
| SCHEMBL12919867 | 0.83 | AKT1 (0.48) | AKT1PDPK1PHLPP1ILKALOX5 | |
| SCHEMBL12919858 | 0.83 | AKT1 (0.48) | AKT1PDPK1PHLPP1ILKALOX5 | |
| SCHEMBL12919857 | 0.83 | AKT1 (0.48) | AKT1PDPK1PHLPP1ILKALOX5 | |
| SCHEMBL12919871 | 0.82 | AKT1 (0.47) | AKT1PDPK1PHLPP1ILKALOX5 | |
| SCHEMBL970854 | 0.81 | AKT1 (0.48) | AKT1PDPK1PHLPP1ILKALOX5 | |
| SCHEMBL12919826 | 0.81 | AKT1 (0.45) | AKT1PDPK1PHLPP1ILKALOX5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7875607-B2 | Neurodegenerative disorders; antiinflammatory agents; antiischemic agents; neuropathic pain; antiepileptic agents; Parkinson's disease; Alzheimer's disease; antidiabetic agents; 3-(6-Hydroxy-2-methyl-3,4,7,8,9,10-hexahydro-7,10-methano-2H -benzo[h]chromen-2-yl)-propionic acid methyl ester | AMPERE LIFE SCIENCES, INC. (US) | 2011-01-25 | — | — | US | claimed |
| US-20090170814-A1 | 7,8-BICYCLOAKYL-CHROMAN DERIVATIVES | EDISON PHARMACEUTICALS, INC. (US) | 2009-07-02 | — | — | US | claimed |
| US-7470798-B2 | Neurodegenerative disorders; antiinflammatory agents; strokes; antiischemic agents; neuropathic pain; brain disorders; antiepileptic agents; Parkinson's disease ; amyotropic lateral sclerosis; Alzheimer's disease; antidiabetic agents | EDISON PHARMACEUTICALS, INC. (US) | 2008-12-30 | — | — | US | claimed |
| US-20050065149-A1 | Neurodegenerative disorders; antiinflammatory agents; strokes; antiischemic agents; neuropathic pain; brain disorders; antiepileptic agents; Parkinson's disease ; amyotropic lateral sclerosis; Alzheimer's disease; antidiabetic agents | PTC THERAPEUTICS, INC. | 2005-03-24 | — | — | US | claimed |
| US-20250325512-A1 | Neurodegenerative Disorders And Muscle Diseases Implicating Pufas | BIOJIVA LLC (US) | 2025-10-23 | — | — | US | disclosed |
| US-12156860-B2 | Disorders implicating PUFA oxidation | BIOJIVA LLC (US) | 2024-12-03 | — | — | US | disclosed |
| US-20230404960-A1 | DISORDERS IMPLICATING PUFA OXIDATION | BIOJIVA LLC (US) | 2023-12-21 | — | — | US | disclosed |
| US-20220378734-A1 | NEURODEGENERATIVE DISORDERS AND MUSCLE DISEASES IMPLICATING PUFAS | RTMFP ENTERPRISES INC. | 2022-12-01 | — | — | US | disclosed |
| US-20220304968-A1 | OXIDATIVE RETINAL DISEASES | BIOJIVA LLC | 2022-09-29 | — | — | US | disclosed |
| US-20220133668-A1 | ISOTOPICALLY MODIFIED COMPONENTS AND THERAPEUTIC USES THEREOF | BIOJIVA LLC | 2022-05-05 | — | — | US | disclosed |
| US-11285125-B2 | Oxidative retinal diseases | RETROTOPE, INC. (US) | 2022-03-29 | — | — | US | disclosed |
| US-11241409-B2 | Neurodegenerative disorders and muscle diseases implicating PUFAs | RETROTOPE, INC. (US) | 2022-02-08 | — | — | US | disclosed |
| US-20140044693-A1 | OXIDATIVE RETINAL DISEASES | RETROTOPE, INC. (US) | 2014-02-13 | — | — | US | disclosed |
| WO-2012148926-A2 | NEURODEGENERATIVE DISORDERS AND MUSCLE DISEASES IMPLICATING PUFAS | RETROTOPE, INC. (US) | 2012-11-01 | — | — | WO | disclosed |
| WO-2012148927-A2 | IMPAIRED ENERGY PROCESSING DISORDERS AND MITOCHONDRIAL DEFICIENCY | RETROTOPE, INC. (US) | 2012-11-01 | — | — | WO | disclosed |
| WO-2012148930-A2 | OXIDATIVE RETINAL DISEASES | RETROTOPE, INC. (US) | 2012-11-01 | — | — | WO | disclosed |
| US-7875607-B2 | Neurodegenerative disorders; antiinflammatory agents; antiischemic agents; neuropathic pain; antiepileptic agents; Parkinson's disease; Alzheimer's disease; antidiabetic agents; 3-(6-Hydroxy-2-methyl-3,4,7,8,9,10-hexahydro-7,10-methano-2H -benzo[h]chromen-2-yl)-propionic acid methyl ester | AMPERE LIFE SCIENCES, INC. (US) | 2011-01-25 | — | — | US | disclosed |
| US-20090170814-A1 | 7,8-BICYCLOAKYL-CHROMAN DERIVATIVES | EDISON PHARMACEUTICALS, INC. (US) | 2009-07-02 | — | — | US | disclosed |
| US-7470798-B2 | Neurodegenerative disorders; antiinflammatory agents; strokes; antiischemic agents; neuropathic pain; brain disorders; antiepileptic agents; Parkinson's disease ; amyotropic lateral sclerosis; Alzheimer's disease; antidiabetic agents | EDISON PHARMACEUTICALS, INC. (US) | 2008-12-30 | — | — | US | disclosed |
| US-20050065149-A1 | Neurodegenerative disorders; antiinflammatory agents; strokes; antiischemic agents; neuropathic pain; brain disorders; antiepileptic agents; Parkinson's disease ; amyotropic lateral sclerosis; Alzheimer's disease; antidiabetic agents | PTC THERAPEUTICS, INC. | 2005-03-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220378734-A1 | NEURODEGENERATIVE DISORDERS AND MUSCLE DISEASES IMPLICATING PUFAS | CPT1B, PSEN2, NLN | AKT1 503/4885PDPK1 294/4885PHLPP1 669/4885 |
| US-11241409-B2 | Neurodegenerative disorders and muscle diseases implicating PUFAs | CPT1B, PSEN2, NLN | AKT1 503/4885PDPK1 294/4885PHLPP1 669/4885 |
| US-12156860-B2 | Disorders implicating PUFA oxidation | GPX4, CPT1A, FABP1 | AKT1 2378/4885PDPK1 952/4885PHLPP1 1759/4885 |
| US-20220304968-A1 | OXIDATIVE RETINAL DISEASES | ALDH1A2, TXNRD2, STARD3 | AKT1 752/4885PDPK1 1160/4885PHLPP1 1860/4885 |
| US-20140044693-A1 | OXIDATIVE RETINAL DISEASES | ALDH1A2, TXNRD2, STARD3 | AKT1 752/4885PDPK1 1160/4885PHLPP1 1860/4885 |
| US-20230404960-A1 | DISORDERS IMPLICATING PUFA OXIDATION | GPX4, CPT1A, FABP1 | AKT1 2378/4885PDPK1 952/4885PHLPP1 1759/4885 |
| US-11285125-B2 | Oxidative retinal diseases | ALDH1A2, TXNRD2, STARD3 | AKT1 752/4885PDPK1 1160/4885PHLPP1 1860/4885 |
| US-20050065149-A1 | Neurodegenerative disorders; antiinflammatory agents; strokes; antiischemic agents; neuropathic pain; brain disorders; antiepileptic agents; Parkinson's disease ; amyotropic lateral sclerosis; Alzheimer's disease; antidiabetic agents | NLN, ACAA2, CS | AKT1 3689/4885PDPK1 903/4885PHLPP1 4163/4885 |
| US-20250325512-A1 | Neurodegenerative Disorders And Muscle Diseases Implicating Pufas | CPT1B, PSEN2, NLN | AKT1 503/4885PDPK1 294/4885PHLPP1 669/4885 |
| US-20220133668-A1 | ISOTOPICALLY MODIFIED COMPONENTS AND THERAPEUTIC USES THEREOF | ACADM, CPT1A, ALDH2 | AKT1 4103/4885PDPK1 2985/4885PHLPP1 3489/4885 |
| US-20090170814-A1 | 7,8-BICYCLOAKYL-CHROMAN DERIVATIVES | COQ8A, TFAM, CS | AKT1 2913/4885PDPK1 362/4885PHLPP1 4378/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.